Plain-English translation of NCT05104736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with thymoma or thymic carcinoma (cancers of the thymus gland) that have come back or are no longer responding to standard chemotherapy. is a first-of-its-kind drug designed to work against cancer cells in multiple ways, including by overcoming the cancer's ability to repair DNA damage and triggering the body's immune system to fight the cancer. Early testing has shown the medication is safe and tolerable, and this trial will determine how well it actually works.
More than half of patients treated with standard chemotherapy for advanced thymus cancer experience their disease coming back and need a second treatment option. Currently there are no approved medications specifically for recurrent thymus cancer, so this trial exists to see if this new treatment can help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through an IV infusion on specific days during 28-day treatment cycles. In the first cycle, you receive two infusions (on days 1 and 15), and then one infusion on day 1 of each following cycle, continuing until your cancer stops responding, side effects become too severe, or for up to 8 years. You'll have regular doctor visits and imaging scans to check how the medication is working and monitor for side effects.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States